Think Outside the Street
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Aegerion's share price has been flying all over the map for the last month. I'll re-enter my down thumb here.The company's only drug in clinical trials is lomitapide, which is in a phase III trial for homozygous familial hypercholesterolemia. Isis hasn't generated much excitement for this niche market with mipomersen, and I don't expect recent upward momentum in Aegerion's share price to be sustained. Ironically, the share price is almost as high as the IPO target of 14 which the company climbed down from just two months ago.